KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Current Taxes (2016 - 2025)

West Pharmaceutical Services' Current Taxes history spans 17 years, with the latest figure at $28.1 million for Q4 2025.

  • For Q4 2025, Current Taxes fell 10.79% year-over-year to $28.1 million; the TTM value through Dec 2025 reached $28.1 million, down 10.79%, while the annual FY2025 figure was $28.1 million, 10.79% down from the prior year.
  • Current Taxes for Q4 2025 was $28.1 million at West Pharmaceutical Services, down from $33.3 million in the prior quarter.
  • Across five years, Current Taxes topped out at $59.0 million in Q1 2023 and bottomed at $15.0 million in Q3 2023.
  • The 5-year median for Current Taxes is $28.3 million (2025), against an average of $29.2 million.
  • The largest annual shift saw Current Taxes surged 257.55% in 2021 before it tumbled 71.53% in 2024.
  • A 5-year view of Current Taxes shows it stood at $26.3 million in 2021, then decreased by 5.7% to $24.8 million in 2022, then plummeted by 33.06% to $16.6 million in 2023, then soared by 89.76% to $31.5 million in 2024, then dropped by 10.79% to $28.1 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Current Taxes are $28.1 million (Q4 2025), $33.3 million (Q3 2025), and $28.5 million (Q2 2025).